| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3874922 | The Journal of Urology | 2008 | 6 Pages |
Abstract
Significant antitumor activity is observed when sorafenib or sunitinib are used in patients who have failed prior therapy with an antiangiogenic agent. Prior response to an antiangiogenic agent does not appear to predict subsequent clinical benefit to either sunitinib or sorafenib.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Ila Tamaskar, Jorge A. Garcia, Paul Elson, Laura Wood, Tarek Mekhail, Robert Dreicer, Brian I. Rini, Ronald M. Bukowski,